TrimRX | AOD-9604 What the Research Actually Says: Evidence Review

Introduction

AOD-9604 has one of the most lopsided gaps in the peptide world between what marketing copy promises and what the published literature shows. Search the compound name and you will find dozens of clinic pages claiming targeted fat burning, joint repair, and growth hormone benefits without growth hormone side effects. The peer reviewed evidence base is thinner than that copy suggests.

This review walks through the actual trials, what they measured, what they found, and what they did not find. The headline is that AOD-9604 failed in late stage obesity development, has some early signal for osteoarthritis, and has never received FDA approval for any indication.

Anyone weighing whether to use AOD-9604, alone or alongside a GLP-1 agonist like semaglutide, deserves a clear picture of the data rather than a curated set of positive abstracts.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Is the History of AOD-9604 Development?

AOD-9604 was developed in the 1990s at Monash University in Australia by researchers studying the fat regulating activity of growth hormone. They identified the carboxyl terminal 16 amino acid fragment of human growth hormone, residues 177 to 191, as containing lipolytic activity that could be separated from the insulin antagonism and skeletal growth effects of the full peptide.

Quick Answer: The Heffernan et al. 2001 trial showed 2.6 kg weight loss versus 0.8 kg placebo over 12 weeks, the strongest published positive result

The compound was licensed to Metabolic Pharmaceuticals, an Australian company, which pursued it as an oral and later injectable obesity therapeutic. Through the early and mid 2000s the program advanced through phase 2 trials in obesity. By 2007 the larger phase 2b results failed to differentiate from placebo on the primary efficacy endpoint, and the obesity program was effectively wound down.

The compound was later repositioned for osteoarthritis, with some interest from Australian and Asian research groups in cartilage applications. It has been classified as a Generally Recognized as Safe ingredient in some food and supplement contexts in Australia and is sold in the United States through compounding pharmacies for unapproved uses.

What Did the Heffernan 2001 Trial Actually Find?

The Heffernan et al. 2001 study in the Journal of Clinical Endocrinology & Metabolism is the most frequently cited human AOD-9604 obesity result. The design was randomized, double blind, placebo controlled, with obese adults receiving daily subcutaneous injections over 12 weeks at doses ranging from 0.25 mg to 1 mg.

Mean weight loss at the 1 mg dose was approximately 2.6 kg versus 0.8 kg in the placebo arm. The trial also measured body composition and reported a shift toward fat mass loss rather than lean mass loss, which was the mechanistic hypothesis. Side effects were limited to headache, mild edema, and occasional fatigue.

The trial was small, around 23 subjects per arm, and short. It established proof of concept rather than clinical efficacy. The effect size was modest, roughly 1.8 kg above placebo over three months, which translates to a marginal clinical benefit by current obesity treatment standards.

What Happened in the Larger Phase 2b Trial?

Metabolic Pharmaceuticals ran a phase 2b trial of AOD-9604 in 534 obese patients over 24 weeks, reporting results in 2007. The trial tested multiple dose arms and a placebo. The primary endpoint was mean percentage weight change from baseline.

The headline result was that AOD-9604 did not separate from placebo on the primary endpoint at any tested dose. The company released a public statement noting the failure of the obesity program. Detailed results were not published in a peer reviewed journal, which is itself a useful signal about how the data looked.

This is the single most important fact about AOD-9604 for weight loss. The key trial in a population large enough to detect a real effect found nothing convincing. Smaller positive trials can be cherry picked. A failed 534 patient trial is harder to explain away.

What Does the Cartilage and Osteoarthritis Evidence Show?

AOD-9604 has been studied for osteoarthritis cartilage repair, primarily in animal models and small human pilot studies. The mechanistic hypothesis is different from the obesity rationale. Researchers proposed AOD-9604 may stimulate chondrocyte activity and matrix production, possibly through pathways involving IGF-1 signaling.

A 2014 publication in the journal Cartilage reported on AOD-9604 administration in knee osteoarthritis with measures of pain and function. The signal was favorable but the trial was small. Subsequent animal work in rabbit and rat OA models has shown cartilage preservation effects.

This is a more interesting line of evidence than the obesity story but it remains preliminary. There is no phase 3 OA trial in humans. The comparator for knee OA pain in a weight relevant population is now STEP 9 (Bliddal et al. 2024 NEJM), which showed semaglutide 2.4 mg produced 41.7 mm WOMAC pain reduction at 68 weeks. Any AOD-9604 OA program would need to differentiate from that benchmark.

How Does AOD-9604 Compare to FDA Approved Obesity Medications?

The contrast is stark. Semaglutide 2.4 mg weekly in STEP 1 (Wilding et al. 2021 NEJM) produced 14.9% mean weight loss over 68 weeks in 1,961 patients. Tirzepatide 15 mg weekly in SURMOUNT-1 (Jastreboff et al. 2022 NEJM) produced 20.9% mean weight loss over 72 weeks in 2,539 patients. Both have hard cardiovascular outcome data. SELECT (Lincoff et al. 2023 NEJM) showed semaglutide reduced major adverse cardiovascular events by 20% in non diabetic patients with established cardiovascular disease and obesity.

AOD-9604 monotherapy at its best published result produced approximately 2.6 kg loss in 12 weeks. There is no cardiovascular outcome data, no cancer surveillance data, no long term safety beyond 24 weeks. The compound is not FDA approved.

For a patient weighing options, this comparison should drive the decision. If the goal is weight loss, the GLP-1 receptor agonists have produced an order of magnitude larger effect with rigorous safety follow up. AOD-9604 is not a substitute.

What Is the Mechanism of Action Evidence?

The proposed mechanism of AOD-9604 is activation of lipolysis through beta 3 adrenergic receptor pathways on adipocytes, plus stimulation of fat oxidation. Preclinical studies in obese mice showed reduced body fat without effects on food intake, which would distinguish it from the appetite suppression mechanism of GLP-1 agonists.

In humans the mechanistic evidence is less clean. The original studies relied on indirect measures of fat oxidation and changes in body composition. Direct measurement of lipolysis through arteriovenous balance studies in adipose tissue has not been published for AOD-9604 in obese humans at clinically relevant doses.

The half life is short, on the order of 30 minutes by some pharmacokinetic estimates, which raises questions about how a once daily injection delivers a sustained metabolic effect.

Key Takeaway: AOD-9604 has never been FDA approved for obesity or any other condition

What Do Users Actually Report?

Self reported experience from peptide forums, telehealth clinic reviews, and case series suggests modest results. Users report weight changes of 2 to 6 pounds over 12 week courses at standard 250 to 500 mcg daily dosing. Some report visible body composition changes, particularly in abdominal fat, that they attribute to the peptide. Others report no detectable effect.

These reports are not controlled. Selection bias is real. Users who paid for a 12 week course and saw nothing are less likely to post. Users who lost weight may attribute changes to AOD-9604 that came from concurrent diet, exercise, or other interventions.

The pattern of reports is consistent with a marginally active or inactive compound rather than a strongly effective one. Compounds with real strong signals, like the GLP-1s, produce consistent and dramatic user reports. AOD-9604 reports are mixed and modest.

Is AOD-9604 a Banned Substance in Sport?

AOD-9604 is on the World Anti Doping Agency prohibited list under section S2 of peptide hormones, growth factors, and related substances. This applies in and out of competition for tested athletes. The classification reflects its structural relationship to growth hormone rather than any proven performance benefit.

Athletes subject to WADA testing should not use AOD-9604. The detection windows for the peptide are not well characterized publicly but the substance class is monitored.

What Safety Information Do We Have?

The published safety database for AOD-9604 is limited. The Heffernan trial and subsequent phase 2 trials reported headache, mild peripheral edema, and occasional fatigue as the most common adverse events. Pancreatic, hepatic, and renal markers were reported as unchanged in the published cohorts.

What we do not have is long term safety beyond 24 weeks, post marketing surveillance data, oncology surveillance, or detailed cardiovascular monitoring at the level required for FDA approval. The compound has never been through phase 3, which is where larger and longer term safety problems typically surface.

This is not a statement that AOD-9604 is unsafe. It is a statement that we do not know what its long term safety profile looks like, and that absence of evidence is not evidence of absence.

How Does the Regulatory Status Affect Access?

AOD-9604 is not FDA approved for any indication. In the United States it is available through compounding pharmacies, typically prescribed off label by telehealth clinics. The FDA has periodically issued warnings about compounded peptides marketed for unapproved uses, and the regulatory landscape has tightened around bulk drug substances since 2023.

Patients should understand they are paying for a non FDA approved compound with no insurance coverage. Quality control depends on the compounding pharmacy. The same active ingredient from different sources may vary in purity.

A free assessment quiz at TrimRx can identify whether your weight loss goals are better served by an FDA approved GLP-1 program with rigorous evidence rather than a compounded peptide with thin data.

What Would a Fair Summary of AOD-9604 Look Like?

A fair summary, written without sales pressure, would say something like this. AOD-9604 is a 16 amino acid fragment of human growth hormone that showed early promise for fat loss in small trials, failed in a 534 patient phase 2b trial in 2007, and is not FDA approved for any indication. There is emerging signal for osteoarthritis cartilage benefit but no phase 3 OA data. The long term safety profile is not characterized. Compared to GLP-1 receptor agonists, the weight loss effect is roughly an order of magnitude smaller and rests on much weaker evidence.

That summary should sit alongside any decision to use the compound. It does not preclude use. It does set the bar where it belongs.

Bottom line: For comparison, semaglutide in STEP 1 produced 14.9% weight loss and tirzepatide in SURMOUNT-1 produced 20.9%, both with hard endpoint cardiovascular data

FAQ

Is AOD-9604 FDA Approved?

No. AOD-9604 is not FDA approved for obesity, osteoarthritis, or any other indication in the United States. It is available only through compounding pharmacies for unapproved uses.

What Is the Largest AOD-9604 Weight Loss Trial?

The 534 patient phase 2b trial run by Metabolic Pharmaceuticals over 24 weeks. The trial did not meet its primary efficacy endpoint and detailed results were not published in a peer reviewed journal.

How Much Weight Loss Can I Expect From AOD-9604?

Based on the best published positive trial, approximately 1.8 kg above placebo over 12 weeks at the 1 mg daily dose. Real world results in users are typically 2 to 6 pounds over a 12 week course, with substantial variation.

Does AOD-9604 Cause Growth Hormone Side Effects?

In published trials it has not produced the insulin resistance, edema, or carpal tunnel symptoms associated with full growth hormone administration. The compound was designed to separate fat metabolism effects from these effects, and that separation appears to hold in the available data.

Is AOD-9604 Better Than Semaglutide for Weight Loss?

No. Semaglutide 2.4 mg weekly produced 14.9% mean weight loss in STEP 1 and 20% MACE reduction in SELECT. AOD-9604 has roughly an order of magnitude smaller effect with no cardiovascular outcome data. The two are not comparable on either efficacy or evidence quality.

Can AOD-9604 Repair Cartilage?

There is preliminary evidence from animal models and small human pilot studies suggesting cartilage benefit in osteoarthritis. No phase 3 trial in humans has been published. The data does not support strong claims of cartilage regeneration.

Is AOD-9604 Banned in Sport?

Yes. AOD-9604 is on the WADA prohibited list under peptide hormones and growth factors. Athletes subject to WADA testing should not use it in or out of competition.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.

AOD-9604 What the Research Actually Says: Evidence Review

Table of Contents